Loading…

Discovery, Synthesis, and Preclinical Characterization of N‑(3-Chloro-4-fluorophenyl)‑1H‑pyrazolo[4,3‑b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)

The efficacy of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclinical rodent models of Parkinson’s disease has been established by a number of groups. Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyr...

Full description

Saved in:
Bibliographic Details
Published in:ACS chemical neuroscience 2016-09, Vol.7 (9), p.1192-1200
Main Authors: Engers, Darren W, Blobaum, Anna L, Gogliotti, Rocco D, Cheung, Yiu-Yin, Salovich, James M, Garcia-Barrantes, Pedro M, Daniels, J. Scott, Morrison, Ryan, Jones, Carrie K, Soars, Matthew G, Zhuo, Xiaoliang, Hurley, Jeremy, Macor, John E, Bronson, Joanne J, Conn, P. Jeffrey, Lindsley, Craig W, Niswender, Colleen M, Hopkins, Corey R
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclinical rodent models of Parkinson’s disease has been established by a number of groups. Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo­[4,3-b]­pyridin-3-amine (VU0418506). We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a number of amide bioisosteres leading to the novel pyrazolo­[4,3-b]­pyridine head group. VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclinical safety species.
ISSN:1948-7193
1948-7193
DOI:10.1021/acschemneuro.6b00035